Formulations for children: Problems and solutions

British Journal of Clinical Pharmacology

Volumn 79, Issue 3, 2015, Pages 405-418

  Batchelor, Hannah K ^a   Marriott, John F ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

bioequivalence; biopharmaceutics; drug formulations; paediatric; pharmacokinetics

Indexed keywords

ARTICLE; CHEWABLE TABLET; DRUG DELIVERY SYSTEM; DRUG FORMULATION; HUMAN; INTRANASAL DRUG ADMINISTRATION; INTRAOCULAR DRUG ADMINISTRATION; INTRAPULMONARY DRUG ADMINISTRATION; LIQUID; MICROCAPSULE; ORAL DRUG ADMINISTRATION; PARENTERAL DRUG ADMINISTRATION; PHARMACOKINETICS; PRIORITY JOURNAL; RECTAL DRUG ADMINISTRATION; SOLID; SOLUTION AND SOLUBILITY; TRANSDERMAL DRUG ADMINISTRATION; CHEMISTRY; CHILD; DRUG DESIGN; DRUG DOSAGE FORM; METABOLISM; THERAPEUTIC EQUIVALENCE;

DRUG; DRUG DOSAGE FORM;

CHILD; DOSAGE FORMS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; PHARMACEUTICAL PREPARATIONS; THERAPEUTIC EQUIVALENCY;

EID: 84929997617     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12268     Document Type: Article

References (119)

1. Gillis J, Loughlan P,. Not just small adults: the metaphors of paediatrics. Arch Dis Child 2007; 92: 946-947.
2. Chamley C, Carson P, Randall D, Sandwell W,. Developmental anatomy and physiology of children-a practical approach: Churchill Livingstone; 2005.
3. McIntosh N, Helms PJ, Smyth RL, Logan S,. Forfar and Arneil's Textbook of Pediatrics, 7th edn. Edinburgh: Elsevier, 2008.
4. Sam T, Ernest TB, Walsh J, Williams JL, on behalf of the European Paediatric Formulation I. A benefit/risk approach towards selecting appropriate pharmaceutical dosage forms An application for paediatric dosage form selection. Int J Pharm 2012; 435: 115-123.
5. Strickley RG, Iwata Q, Wili S, Dahl TC,. Pediatric drugs-A review of commercially available oral formulations. J Pharm Sci 2008; 97: 1731-1774.
6. Breitkreutz J, Boos J,. Drug delivery and formulations. Handb Exp Pharmacol 2011; 205: 91-107.
7. EMA. Guideline on pharmaceutical development of medicines for paediatric use, Rev.1. EMA/CHMP/QWP/805880/2012 2013; Available at: http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2013/01/WC500137023.pdf (last accessed 11 October 2013).
8. IOM. Safe and effective medicines for children: pediatric studies conducted under BPCA and PREA. Consensus Report. 2012; Available at: http://www.iom.edu/Reports/2012/Safe-and-Effective-Medicines-for-Children.aspx (last accessed 11 October 2013).
9. WHO. Development of paediatric medicines: points to consider in formulation. WHO Expert Committee on Specifications for Pharmaceutical Preparations WHO Technical Report Series No 970. 2012;Forty-sixth report 197-225.
10. EMA. ICH E11 Clinical Investigation of Medicinal Products in the Paediatric Population. 2011; Available at: http://jppsg.ac.uk/racdv/resgov/Resources/271199en.pdf (last accessed 11 October 2013).
11. EMA. Draft Guideline on Pharmaceutical Development of Medicines for Paediatric Use. EMA/CHMP/QWP/180157/2011 Committee for Medicinal Products for Human Use (CHMP). 2011.
12. Edginton AN, Fotaki N,. Oral drug absorption in pediatric populations. In: Oral Drug Absorption: Prediction and Assessment, 2nd edn. eds, Dressman J, Reppas C,. New York: Informa Healthcare, 2010; 108-126.
13. Richey RH, Shah UU, Peak M, Craig JV, Ford JL, Barker CE, Nunn AJ, Turner MA,. Manipulation of drugs to achieve the required dose is intrinisic to paediatric practice but is not supported by guidelines or evidence. BMC Pediatr 2013; 13: 1-8.
14. EMA. Revised provisional priority list for studies into off-patent paediatric medicinal products EMA/98717/2012 Human Medicines Development and Evaluation. 2013.
15. WHO. WHO Model List of Essential Medicines for Children. 2013.
16. Tomlin S, Cokerill H, Costello I, Griffith R, Hicks R, Sutcliffe A, Tuleu C,. Making medicines safer for children-guidance on the use of unlicensed medicines in paediatric patients. Guidelines handbook. Nursingtimesnet. 2009.
17. FDA. Guidance for industry: food-effect bioavailability and fed bioequivalence studies. In: U.S. Department of Health and Human Services CfDEaRC, editor. 2002.
18. Falchook GS, Sarantopoulos J, Kurzrock R, Mita AC, Fu S, Mita MM, Zhou X, Milch C, Jung J, Venkatakrishnan K, Rosen LS,. Phase 1 relative bioavailability study of a prototype oral solution (OS) formulation of the investigational Aurora A kinase (AAK) inhibitor alisertib (MLN8237) in reference to a powder-in-capsule (PIC) formulation in patients with advanced solid tumors. Mol Cancer Ther 2011; 10: (11 Suppl. 1): B194.
19. Lyszkiewicz DA, Levichek Z, Kozer E, Yagev Y, Moretti M, Hard M, Koren G,. Bioavailability of a pediatric amlodipine suspension. Pediatr Nephrol 2003; 18: 675-678.
20. Djimdé AA, Tekete M, Abdulla S, Lyimo J, Bassat Q, Mandomando I, Lefèvre G, Borrmann S, Group BS,. Pharmacokinetic and pharmacodynamic characteristics of a new pediatric formulation of artemether-lumefantrine in African children with uncomplicated Plasmodium falciparum malaria. Antimicrob Agents Chemother 2011; 55: 3994-3999.
21. Abdulla S, Amuri B, Kabanywanyi AM, Ubben D, Reynolds C, Pascoe S, Fitoussi S, Yeh C-M, Nuortti M, Séchaud R, Kaiser G, Lefèvre G,. Early clinical development of artemether-lumefantrine dispersible tablet: palatability of three flavours and bioavailability in healthy subjects. Malar J 2010; 9: 253.
22. Ramharter M, Kurth FM, Bélard S, Bouyou-Akotet MK, Mamfoumbi MM, Agnandji ST, Missinou MA, Adegnika AA, Issifou S, Cambon N, Heidecker JL, Kombila M, Kremsner PG,. Pharmacokinetics of two paediatric artesunate mefloquine drug formulations in the treatment of uncomplicated falciparum malaria in Gabon. J Antimicrob Chemother 2007; 60: 1091-1096.
23. Gutierrez MM, Nicolas LB, Donazzolo Y, Dingemanse J,. Relative bioavailability of a newly developed pediatric formulation of bosentan vs. the adult formulation. Int J Clin Pharmacol Ther 2013; 51: 529-536.
24. Teng R, Hansson AC, Borjesson I,. Oral bioavailability of candesartan cilexetil suspension. J Pharm Technol 2007; 23: 270-274.
25. Zou J, Di B, Wu CY, Hu Q, Li JH, Zhu Y, Fan H, Xiao D, Wang GJ,. Pharmacokinetic and bioequivalence comparison of a single 100 mg dose of cefteram pivoxil powder suspension and tablet formulations: a randomized-sequence, open-label, two-period crossover study in healthy chinese adult male volunteers. Clin Ther 2008; 30: 654-660.
26. Kees F, Bucher M, Schweda F, Gschaidmeier H, Faerber L, Seifert R,. Neoimmun versus Neoral: a bioequivalence study in healthy volunteers and influence of a fat-rich meal on the bioavailability of Neoimmun. Naunyn Schmiedebergs Arch Exp Pathol Pharmakol 2007; 375: 393-399.
27. Whipple JK, Lewis KS, Weitman SD, Ausman RK, Bourne DW, Andrews W, Adams MB, Sasse EA, Quebbeman EJ,. Pharmacokinetic evaluation of a new oral cyclosporine formulation. Pharmacotherapy 1994; 14: 105-110.
28. Acott PD, Crocker JF, Renton KW,. Evaluation of performance factors affecting two formulations of cyclosporine in pediatric renal transplant patients. Transplant Proc 2006; 38: 2835-2841.
29. van Mourik ID, Thomson M, Kelly DA,. Comparison of pharmacokinetics of Neoral and Sandimmune in stable pediatric liver transplant recipients. Liver Transpl Surg 1999; 5: 107-111.
30. De Guchtenaere A, Van Herzeele C, Raes A, Dehoorne J, Hoebeke P, Van Laecke E, Van Laecke E, Vande Walle J,. Oral Lyophylizate formulation of desmopressin: superior pharmacodynamics compared to tablet due to low food interaction. J Urol 2011; 185: 2308-2313.
31. Queckenberg C, Wachall B, Erlinghagen V, Di Gion P, Tomalik-Scharte D, Tawab M, Gerbeth K, Fuhr U,. Pharmacokinetics, pharmacodynamics, and comparative bioavailability of single, oral 2-mg doses of dexamethasone liquid and tablet formulations: a randomized, controlled, crossover study in healthy adult volunteers. Clin Ther 2011; 33: 1831-1841.
32. Kim K-A, Lim JL, Kim C, Park J-Y,. Pharmacokinetic comparison of orally disintegrating and conventional donepezil formulations in healthy Korean male subjects: a single-dose, randomized, open-label, 2-sequence, 2-period crossover study. Clin Ther 2011; 33: 965-972.
33. ter Heine R, Scherpbier HJ, Crommentuyn KML, Bekker V, Beijnen JH, Kuijpers TW, Huitema ADR,. A pharmacokinetic and pharmacogenetic study of efavirenz in children: dosing guidelines can result in subtherapeutic concentrations. Antivir Ther 2008; 13: 779-787.
34. Wire MB, Bruce J, Gauvin J, Pendry CJ, McGuire S, Qian Y, Brainsky A,. A randomized, open-label, 5-period, balanced crossover study to evaluate the relative bioavailability of eltrombopag powder for oral suspension (PfOS) and tablet formulations and the effect of a high-calcium meal on eltrombopag pharmacokinetics when administered with or 2 hours before or after PfOS. Clin Ther 2012; 34: 699-709.
35. Wang LH, Wiznia AA, Rathore MH, Chittick GE, Bakshi SS, Emmanuel PJ, Flynn PM,. Pharmacokinetics and safety of single oral doses of emtricitabine in human immunodeficiency virus-infected children. Antimicrob Agents Chemother 2004; 48: 183-191.
36. Kovarik JM, Noe A, Berthier S, McMahon L, Langholff WK, Marion AS, Hoyer PF, Ettenger R, Rordorf C,. Clinical development of an everolimus pediatric formulation: relative bioavailability, food effect, and steady-state pharmacokinetics. J Clin Pharmacol 2003; 43: 141-147.
37. Monif T, Rao Thudi N, Koundinya Tippabhotla S, Khuroo A, Marwah A, Kumar Shrivastav V, Tandon M, Raghuvanshi R, Biswal S,. A single-dose, randomized, open-label, two-period crossover bioequivalence study of a fixed-dose pediatric combination of lamivudine 40-mg, nevirapine 70-mg, and stavudine 10-mg tablet for oral suspension with individual liquid formulations in healthy adult male volunteers. Clin Ther 2007; 29: 2677-2684.
38. Monif T, Reyar S, Tiwari HK, Tippabhotla SK, Khuroo A, Thudi NR, Ahmed S, Raghuvanshi R,. A single-dose, randomized, open-label, two-period crossover bioequivalence study comparing a fixed-dose pediatric combination of lamivudine and stavudine tablet for oral suspension with individual liquid formulations in healthy adult male volunteers. Arzneimittelforschung 2009; 59: 104-108.
39. Liu Y-M, Liu G-Y, Liu Y, Li S-J, Jia J-Y, Zhang M-Q, Lu C, Zhang Y-M, Li X-N, Yu C,. Pharmacokinetic and bioequivalence comparison between orally disintegrating and conventional tablet formulations of flurbiprofen: a single-dose, randomized-sequence, open-label, two-period crossover study in healthy chinese male volunteers. Clin Ther 2009; 31: 1787-1795.
40. de Montalembert M, Bachir D, Hulin A, Gimeno L, Mogenet A, Bresson JL, Macquin-Mavier I, Roudot-Thoraval F, Astier A, Galacteros F,. Pharmacokinetics of hydroxyurea 1,000 mg coated breakable tablets and 500 mg capsules in pediatric and adult patients with sickle cell disease. Haematologica 2006; 91: 1685-1688.
41. Marcelín-Jiménez G, Angeles-Moreno AP, Contreras-Zavala L, Morales-Martínez M, Rivera-Espinosa L,. A single-dose, three-period, six-sequence crossover study comparing the bioavailability of solution, suspension, and enteric-coated tablets of magnesium valproate in healthy Mexican volunteers under fasting conditions. Clin Ther 2009; 31: 2002-2011.
42. Knorr B, Hartford A, Li X, Yang AY, Noonan G, Migoya E,. Bioequivalence of the 4-mg Oral Granules and Chewable Tablet Formulations of Montelukast. Arch Drug Inf 2010; 3: 37-43.
43. Zhang Q, Tao Y, Zhu Y, Zhu D,. Bioequivalence and pharmacokinetic comparison of two mycophenolate mofetil formulations in healthy Chinese male volunteers: an open-label, randomized-sequence, single-dose, two-way crossover study. Clin Ther 2010; 32: 171-178.
44. Abdel-Rahman SM, Johnson FK, Gauthier-Dubois G, Weston IE, Kearns GL,. The bioequivalence of nizatidine (Axid) in two extemporaneously and one commercially prepared oral liquid formulations compared with capsule. J Clin Pharmacol 2003; 43: 148-153.
45. Armando YP, Schramm SG, de Freitas Silva M, Kano EK, Koono EEM, Porta V, dos Reis Serra CH,. Bioequivalence assay between orally disintegrating and conventional tablet formulations in healthy volunteers. Int J Pharm 2009; 366: 149-153.
46. Ahmed M, Morrel EM, Clemente E,. Bioavailability and pharmacokinetics of a new liquid prednisolone formulation in comparison with two commercially available liquid prednisolone products. Curr Ther Res Clin Exp 2001; 62: 548-556.
47. Juarez Olguin H, Flores Perez C, Ramirez Mendiola B, Barranco Garduno L, Sandoval Ramirez E, Flores Perez J,. Comparative bioavailability of propafenone after administration of a magistral suspension vs. commercial tablets in healthy volunteers. Arzneimittelforschung 2009; 59: 117-120.
48. Huang M, Shen-Tu J, Hu X, Chen J, Liu J, Wu L,. Comparative fasting bioavailability of dispersible and conventional tablets of risperidone: a single-dose, randomized-sequence, open-label, two-period crossover study in healthy male Chinese volunteers. Clin Ther 2012; 34: 1432-1439.
49. Critchley D,. 1FC1.2 a novel rufinamide oral liquid/suspension formulation for Lennox-Gastaut syndrome patients. Eur J Paediatr Neurol 2011; 15: (Suppl 1): S10.
50. Mulligan S, Devane J, Martin M,. Pharmacokinetic characteristics of a novel controlled-release sprinkle formulation of salbutamol. Eur J Drug Metab Pharmacokinet 1991; 3: (Spec No 3): 312-314.
51. Gao X, Robert L, O'Gorman M, Cook J,. A newly developed pediatric formulation of revatio for pediatric pulmonary arterial hypertension patients is bioequivalent to the 1X20 MG revatio commercial tablet and to the 2X10 MG sildenafil citrate clinical trial tablets in healthy adult volunteers. Clin Pharmacol Ther 2012; 91: S38-39.
52. Liedert B, Forssmann U, Wolna P, Golob M, Kovar A,. Comparison of the pharmacokinetics, safety and tolerability of two concentrations of a new liquid recombinant human growth hormone formulation versus the freeze-dried formulation. BMC Clin Pharmacol 2010; 10: 14.
53. Innes S, Norman J, Smith P, Smuts M, Capparelli E, Rosenkranz B, Cotton M,. Bioequivalence of dispersed stavudine: opened versus closed capsule dosing. Antivir Ther 2011; 16: 1131-1134.
54. Vanprapar N, Cressey TR, Chokephaibulkit K, Muresan P, Plipat N, Sirisanthana V, Prasitsuebsai W, Hongsiriwan S, Chotpitayasunondh T, Eksaengsri A, Toye M, Smith ME, McIntosh K, Capparelli E, Yogev R, Team IP,. A chewable pediatric fixed-dose combination tablet of stavudine, lamivudine, and nevirapine: pharmacokinetics and safety compared with the individual liquid formulations in human immunodeficiency virus-infected children in Thailand. Pediatr Infect Dis J 2010; 29: 940-944.
55. DuBois SG, Shusterman S, Reid JM, Ingle AM, Ahern CH, Baruchel S, Glade-Bender J, Ivy P, Adamson PC, Blaney SM,. Tolerability and pharmacokinetic profile of a sunitinib powder formulation in pediatric patients with refractory solid tumors: a Children's Oncology Group study. Cancer Chemother Pharmacol 2012; 69: 1021-1027.
56. Campos A, Espinosa L, Medrano N, Alonso-Melgar A, Alonso L, Nuno-Almeida G, Tong H, Ramirez E, Frias-Iniesta J, Carcas-Sansuan AJ,. Relative bioavailability of two tacrolimus formulations: Prograf (normal release) and Advagraf (sustained release) in children with kidney transplant. Basic Clin Pharmacol Toxicol 2011; 109: 46 (Meeting Abstract. FI-2,371. Q2).
57. Daw NC, Santana VM, Iacono LC, Furman WL, Hawkins DR, Houghton PJ, Panetta JC, Gajjar AJ, Stewart CF,. Phase I and pharmacokinetic study of topotecan administered orally once daily for 5 days for 2 consecutive weeks to pediatric patients with refractory solid tumors. J Clin Oncol 2004; 22: 829-837.
58. Setchell KDR, Galzigna L, O′Connell N, Brunetti G, Tauschel HD,. Bioequivalence of a new liquid formulation of ursodeoxycholic acid (Ursofalk suspension) and Ursofalk capsules measured by plasma pharmacokinetics and biliary enrichment. Aliment Pharmacol Ther 2005; 21: 709-721.
59. Pescovitz MD, Jain A, Robson R, Mulgaonkar S, Freeman R, Bouw MR,. Establishing pharmacokinetic bioequivalence of valganciclovir oral solution versus the tablet formulation. Transplant Proc 2007; 39: 3111-3116.
60. Verrotti A, Nanni G, Agostinelli S, Alleva ET, Aloisi P, Franzoni E, Spalice A, Chiarelli F, Coppola G,. Effects of the abrupt switch from solution to modified-release granule formulation of valproate. Acta Neurol Scand 2012; 125: e14-18.
61. Kayitare E, Vervaet C, Ntawukulilyayo JD, Seminega B, Van Bortel L, Remon JP,. Development of fixed dose combination tablets containing zidovudine and lamivudine for paediatric applications. Int J Pharm 2009; 31: 41-46.
62. Chokephaibulkit K, Cressey TR, Capparelli E, Sirisanthana V, Muresan P, Hongsiriwon S, Ngampiyaskul C, Limwongse C, Wittawatmongkol O, Aurpibul L, Kabat B, Toye M, Smith ME, Eksaengsri A, McIntosh K, Yogev R,. Pharmacokinetics and safety of a new paediatric fixed-dose combination of zidovudine/lamivudine/nevirapine in HIV-infected children. Antivir Ther 2011; 16: 1287-1295.
63. Kasirye P, Kendall L, Adkison KK, Tumusiime C, Ssenyonga M, Bakeera-Kitaka S, Nahirya-Ntege P, Mhute T, Kekitiinwa A, Snowden W, Burger DM, Gibb DM, Walker AS, Team AT,. Pharmacokinetics of antiretroviral drug varies with formulation in the target population of children with HIV-1. Clin Pharmacol Ther 2012; 91: 272-280.
64. Ernest TB, Elder DP, Martini L, Roberts M, Ford JL,. Developing paediatric medicines:identifying the needs and recognizing the challenges. J Pharm Pharmacol 2007; 59: 1043-1055.
65. Tuleu C, Breitkreutz J,. Educational Paper: formulation-related issues in pediatric clinical pharmacology. Eur J Pediatr 2013; 172: 717-720.
66. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE,. Developmental pharmacology-drug disposition, action, and therapy in infants and children. N Engl J Med 2003; 349: 1157-1167.
67. Glendinning JI,. Is the bitter rejection response always adaptive? Physiol Behav 1994; 56: 1217-1227.
68. Milne CP, Bruss JB,. The economics of pediatric formulation development for off-patent drugs. Clin Ther 2008; 30: 2133-2145.
69. Collins FJ, Matthews HR, Baker SE, Strakova JM,. Drug-induced oesophageal injury. BMJ 1979; 1: 1673-1676.
70. Paparella S,. Identified safety risks with splitting and crushing oral medications. J Emerg Nurs 2010; 36: 156-158.
71. Thomson SA, Tuleu C, Wong ICK, Keady S, Pitt KG, Sutcliffe AG,. Minitablets: new modality to deliver medicines to preschool-aged children. Pediatrics 2009; 123: e235-238.
72. Spomer N, Klingmann V, Stoltenberg I, Lerch C, Meissner T, Breitkreutz J,. Acceptance of uncoated mini-tablets in young children: results from a prospective exploratory cross-over study. Arch Dis Child 2012; 97: 283-286.
73. FDA. Guidance for Industry. Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System. US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). 2000.
74. Sunesen VH, Vedelsdal R, Kristensen HG, Christrup L, Müllertz A,. Effect of liquid volume and food intake on the absolute bioavailability of danazol, a poorly soluble drug. Eur J Pharm Sci 2005; 24: 297-303.
75. Matsumoto F, Sakurai I, Morita M, Takahashi T, Mori N, Sugihara T, Sakai A, Yamaji S, Akaike Y, Yano K,. Effects of the quantity of water and milk ingested concomitantly with AS-924, a novel ester-type cephem antibiotic, on its pharmacokinetics. Int J Antimicrob Agents 2001; 18: 471-476.
76. Lottman H, Froeling F, Alloussi S, El-Radhi AS, Rittig S, Riis A, Persson B-E,. A randomised comparison of oral desmopressin lyophilisate (MELT) and tablet formulations in children and adolescents with primary nocturnal enuresis. Int J Clin Pract 2007; 61: 1454-1460.
77. Mennella JA, Spector AC, Reed DR, Coldwell SE,. The bad taste of medicines: overview of basic research on bitter taste. Clin Ther 2013; 35: 1225-1246.
78. Paediatric dosing guidelines should integrate the four most important developmental pharmacokinetic processes. Drugs Ther Perspect 2007; 23: 23-26.
79. Cumberland PM, Pathai S, Rahi JS, Millennium Cohort Study Child Health G. Prevalence of eye disease in early childhood and associated factors: findings from the millennium cohort study. Ophthalmology 2010; 117: 2184-2190.
80. Isenberg SJ, Apt L, McCarty J, Cooper LL, Lim L, Del Signore M,. Development of tearing in preterm and term neonates. Arch Ophthalmol 1998; 116: 773-776.
81. Friedman TS, Patton TF,. Differences in ocular penetration of pilocarpine in rabbits of different ages. J Pharm Sci 1976; 65: 1095-1096.
82. Francoeur M, Ahmed I, Sitek S, Patton TF,. Age-related differences in ophthalmic drug disposition III. Corneal permeability of pilocarpine in rabbits. Int J Pharm 1983; 16: 203-213.
83. Patton TF, Robinson JR,. Pediatric dosing considerations in ophthalmology. J Pediatr Ophthalmol 1976; 13: 171-178.
84. Macdonald EA, Maurice DM,. Loss of fluorescein across the conjunctiva. Exp Eye Res 1991; 53: 427-430.
85. Esmaeelpour M, Watts PO, Boulton ME, Cai J, Murphy PJ,. Tear film volume and protein analysis in full-term newborn infants. Cornea 2011; 30: 400-404.
86. Levy Y, Zadok D,. Systemic side effects of ophthalmic drops. Clin Pediatr (Phila) 2004; 43: 99-101.
87. Berlin RJ, Lee UT, Samples JR, Rich LF, Tang-Liu DDS, Sing KA, Steiner RD,. Ophthalmic drops causing coma in an infant. J Pediatr 2001; 138: 441-443.
88. Passo MS, Palmer EA, Van Buskirk EM,. Plasma timolol in glaucoma patients. Ophthalmology 1984; 91: 1361-1363.
89. Raber S, Courtney R, Maeda-Chubachi T, Simons BD, Freedman SF, Wirostko B,. Latanoprost systemic exposure in pediatric and adult patients with glaucoma: a phase 1, open-label study. Ophthalmology 2011; 118: 2022-2027.
90. Patton TF,. Pediatric dosing considerations in ophthalmology-dosage adjustments based on aqueous humor volume ratio. J Pediatr Ophthalmol 1977; 14: 254-256.
91. Noh H, Lee D-H,. Direct measurement of ear canal volume in a pediatric population: can we explain its individual variation in terms of age and body weight? Int J Pediatr Otorhinolaryngol 2012; 76: 658-662.
92. Shanks JE, Lilly DJ,. An evaluation of tympanometric estimates of ear canal volume. J Speech Hear Res 1981; 24: 557-566.
93. Woody RC, Golladay ES, Fiedorek SC,. Rectal anticonvulsants in seizure patients undergoing gastrointestinal surgery. J Pediatr Surg 1989; 24: 474-477.
94. Valentin J,. Basic anatomical and physiological data for use in radiological protection: reference values: ICRP Publication 89. Ann ICRP 2002; 32: 1-277.
95. Joensson IM, Siggaard C, Rittig S, Hagstroem S, Djurhuus JC,. Transabdominal ultrasound of rectum as a diagnostic tool in childhood constipation. J Urol 2008; 179: 1997-2002.
96. van Lingen RA, Deinum JT, Quak JME, Kuizenga AJ, van Dam JG, Anand KJS, Tibboel D, Okken A,. Pharmacokinetics and metabolism of rectally administered paracetamol in preterm neonates: presented in part at the annual meeting of the European Society for Pediatric Research, Rotterdam, The Netherlands, July 3-6 1994. Arch Dis Child 1999; 80: F59-F63.
97. Graves NM, Kriel RL,. Rectal administration of antiepileptic drugs in children. Pediatr Neurol 1987; 3: 321-326.
98. Dhillon S, Ngwane E, Richens A,. Rectal absorption of diazepam in epileptic children. Arch Dis Child 1982; 57: 264-267.
99. Walters MCn, Furyk J,. Paediatric intramuscular injections for developing world settings: a review of the literature for best practices. J Transcult Nurs 2012; 23: 406-409.
100. Greenblatt DJ,. Intramuscular injection of drugs. N Engl J Med 1976; 295: 542-546.
101. Kafetzis DA, Sinaniotis CA, Papadatos CJ, Kosmidis J,. Pharmacokinetics of amikacin in infants and pre-school children. Acta Paediatr Scand 1979; 68: 419-422.
102. Sheng KT, Huang NN, Promadhattavedi V,. Serum concentrations of cephalothin in infants and children and placental transmission of the antibiotic. Antimicrob Agents Chemother 1964; 10: 200-206.
103. Laursen T, Hansen B, Fisker S,. Pain perception after subcutaneous injections of media containing different buffers. Basic Clin Pharmacol Toxicol 2006; 98: 218-221.
104. Watt S,. Safe administration of medicines to children: part 2. Paediatr Nurs 2003; 15: 40-44.
105. Brearley C, Priestley A, Leighton-Scott J, Christen M,. Pharmacokinetics of recombinant human growth hormone administered by cool.click 2, a new needle-free device, compared with subcutaneous administration using a conventional syringe and needle. BMC Clin Pharmacol 2007; 7: 10.
106. Shah UU, Roberts M, Orlu Gul M, Tuleu C, Beresford MW,. Needle-free and microneedle drug delivery in children: a case for disease-modifying antirheumatic drugs (DMARDs). Int J Pharm 2011; 416: 1-11.
107. Schneider U, Birnbacher R, Schober E,. Painfulness of needle and jet injection in children with diabetes mellitus. Eur J Pediatr 1994; 153: 409-410.
108. Beaney AM,. Preparation of parenteral medicines in clinical areas: how can the risks be managed-a UK perspective? J Clin Nurs 2010; 19: 1569-1577.
109. Nikolovski J, Stamatas GN, Kollias N, Wiegand BC,. Barrier function and water-holding and transport properties of infant stratum corneum are different from adult and continue to develop through the first year of life. J Invest Dermatol 2008; 128: 1728-1736.
110. Choonara I,. Percutaneous drug absorption and administration. Arch Dis Child 1994; 71: F73-74.
111. Peleg O, Bar-Oz B, Arad I,. Coma in a premature infant associated with the transdermal absorption of propylene glycol. Acta Pædiatrica 1998; 87: 1195-1196.
112. Fink JB,. Delivery of inhaled drugs for infants and small children: a commentary on present and future needs. Clin Ther 2012; 34: S36-S45.
113. Lowenthal D, Kattan M,. Facemasks versus mouthpieces for aerosol treatment of asthmatic children. Pediatr Pulmonol 1992; 14: 192-196.
114. Mellon M, Leflein J, Walton-Bowen K, Cruz-Rivera M, Fitzpatrick S, Smith JA,. Comparable efficacy of administration with face mask or mouthpiece of nebulized budesonide inhalation suspension for infants and young children with persistent asthma. Am J Respir Crit Care Med 2000; 162: (2 I): 593-598.
115. Venables R, Marriott J, Stirling H,. FIND OUT: key problems with children's medicines formulations ⋯ It's a taste issue! Int J Pharm Pract 2012; 20: (S2): 23.
116. Fabiano V, Mameli C, Zuccotti GV,. Paediatric pharmacology: remember the excipients. Pharmacol Res 2011; 63: 362-365.
117. Nahata MC,. Safety of 'inert' additives or excipients in paediatric medicines. Arch Dis Child 2009; 94: F392-393.
118. Salunke S, Giacoia G, Tuleu C,. The STEP (Safety and Toxicity of Excipients for Paediatrics) database. Part 1 A need assessment study. Int J Pharm 2012; 435: 101-111.
119. Baguley D, Lim E, Bevan A, Pallet A, Faust SN,. Prescribing for children-taste and palatability affect adherence to antibiotics: a review. Arch Dis Child 2012; 97: 293-297.